Schonfeld Strategic Advisors LLC Has $3.96 Million Stake in Dynavax Technologies Co. (NASDAQ:DVAX)

Schonfeld Strategic Advisors LLC grew its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 97.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 310,430 shares of the biopharmaceutical company's stock after acquiring an additional 153,302 shares during the period. Schonfeld Strategic Advisors LLC owned 0.24% of Dynavax Technologies worth $3,964,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in DVAX. Barclays PLC raised its stake in Dynavax Technologies by 137.4% during the 3rd quarter. Barclays PLC now owns 302,572 shares of the biopharmaceutical company's stock worth $3,371,000 after buying an additional 175,118 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in shares of Dynavax Technologies during the third quarter worth approximately $89,000. Franklin Resources Inc. lifted its holdings in shares of Dynavax Technologies by 5.7% in the 3rd quarter. Franklin Resources Inc. now owns 82,415 shares of the biopharmaceutical company's stock worth $862,000 after purchasing an additional 4,459 shares in the last quarter. GAMMA Investing LLC grew its position in Dynavax Technologies by 55.1% in the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company's stock valued at $52,000 after purchasing an additional 1,457 shares during the period. Finally, Nordea Investment Management AB increased its stake in Dynavax Technologies by 42.7% during the 4th quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company's stock valued at $10,034,000 after purchasing an additional 232,690 shares in the last quarter. 96.96% of the stock is owned by institutional investors.

Dynavax Technologies Stock Performance

Shares of DVAX opened at $11.33 on Friday. Dynavax Technologies Co. has a 52-week low of $9.74 and a 52-week high of $14.63. The stock's 50-day simple moving average is $12.59 and its 200 day simple moving average is $12.59. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The stock has a market capitalization of $1.39 billion, a price-to-earnings ratio of 62.94 and a beta of 1.26.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, hitting the consensus estimate of $0.05. The firm had revenue of $72.03 million for the quarter, compared to analysts' expectations of $72.70 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. Research analysts forecast that Dynavax Technologies Co. will post 0.32 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on DVAX. William Blair reaffirmed an "outperform" rating on shares of Dynavax Technologies in a research report on Friday, February 21st. HC Wainwright reissued a "buy" rating and issued a $31.00 price target on shares of Dynavax Technologies in a research report on Friday, February 21st. The Goldman Sachs Group cut their price objective on shares of Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a report on Thursday, April 17th. Finally, StockNews.com upgraded shares of Dynavax Technologies from a "hold" rating to a "buy" rating in a report on Monday, February 24th.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.